Carisbamate Clinical Trials (2026): 13 Studies for Epilepsy, Complex Partial & Lennox Gastaut Syndrome
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
13 Carisbamate clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 10 indications (including Epilepsy, Complex Partial & Lennox Gastaut Syndrome) and 3,030 total planned enrollment. 5 Phase 3 Carisbamate trials and 4 Phase 2 are listed. 1 Carisbamate clinical trial is actively recruiting at 7 U.S. sites across 6 states. Most recent activity: NCT05219617 (Dec 2028).
Where to Participate: All Carisbamate Trial Sites in the U.S. (7 sites across 6 states)
Every actively recruiting Carisbamatetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Stanford University Hospital | Palo Alto94305 | NCT05219617 | Map |
| FL | Pediatric Epilepsy and Neurology Specialists | Tampa33609 | NCT05219617 | Map |
| MD | Johns Hopkins Hospital | Baltimore21287 | NCT05219617 | Map |
| MD | Mid-Atlantic Epilepsy and Sleep Center | Bethesda20817 | NCT05219617 | Map |
| NJ | Northeast Regional Epilepsy Group | Hackensack07601 | NCT05219617 | Map |
| NC | Duke University Clinical Research at Pickett Road | Durham27713 | NCT05219617 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT05219617 | Map |
Carisbamate clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | terminated | Total |
|---|---|---|---|---|
| P1 | 3 | 3 | ||
| P1/P2 | 1 | 1 | ||
| P2 | 4 | 4 | ||
| P3 | 1 | 3 | 1 | 5 |
Recruiting Carisbamate clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05219617 | Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | P3 | Seizures | 252 | Apr 2022 |
Carisbamate clinical trials by indication
Lennox Gastaut Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04062981 | — | P1 | completed | Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome |
| NCT03731715 | — | P1 | completed | Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome |
Epilepsy, Partial, Motor (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00744731 | — | P3 | completed | An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures |
| NCT00740623 | — | P3 | completed | A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures. |
Epilepsy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00991757 | — | P3 | completed | An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures. |
| NCT00563459 | — | P3 | terminated | Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy. |
Seizures (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05219617 | — | P3 | recruiting | Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults |
Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04520360 | — | P1 | completed | Bioavailability and Food Effect Study of 3 Types of Carisbamate |
Alcohol Dependence (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02435381 | — | P1/P2 | completed | Carisbamate as a Potential Treatment for Alcohol Dependence |
Diabetic Neuropathies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00870454 | — | P2 | completed | An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics |
Essential Tremor, Movement Disorders (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00524056 | — | P2 | completed | A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor |
Diabetic Neuropathy, Painful (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00501202 | DPN | P2 | completed | Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN). |
Postherpetic Neuralgia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00492323 | PHN | P2 | completed | An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN). |
Carisbamate pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| PHN | NCT00492323 | P2 | completed | Postherpetic Neuralgia | 91 | — |
| DPN | NCT00501202 | P2 | completed | Diabetic Neuropathy, Painful | 132 | — |
Terminated and withdrawn Carisbamate trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT00563459terminatedCarisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.
All Carisbamate trials (13)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05219617 | Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | P3 | recruiting | 252 | SK Life Science, Inc. | Apr 2022 | |
| NCT04062981 | Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome | P1 | completed | 15 | SK Life Science, Inc. | May 2019 | |
| NCT03731715 | Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome | P1 | completed | 18 | SK Life Science, Inc. | Feb 2019 | |
| NCT04520360 | Bioavailability and Food Effect Study of 3 Types of Carisbamate | P1 | completed | 33 | SK Life Science, Inc. | Aug 2020 | |
| NCT02435381 | Carisbamate as a Potential Treatment for Alcohol Dependence | P1/P2 | completed | 11 | Baylor College of Medicine | Feb 2013 | |
| NCT00870454 | An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics | P2 | completed | 386 | SK Life Science, Inc. | May 2009 | |
| NCT00991757 | An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures. | P3 | completed | 991 | SK Life Science, Inc. | Feb 2007 | |
| NCT00744731 | An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures | P3 | completed | 403 | SK Life Science, Inc. | Jan 2009 | |
| NCT00740623 | A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures. | P3 | completed | 547 | SK Life Science, Inc. | Jan 2009 | |
| NCT00563459 | Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy. | P3 | terminated | 89 | SK Life Science, Inc. | Nov 2007 | |
| NCT00492323 | PHN | An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN). | P2 | completed | 91 | SK Life Science, Inc. | Mar 2007 |
| NCT00501202 | DPN | Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN). | P2 | completed | 132 | SK Life Science, Inc. | Mar 2007 |
| NCT00524056 | A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor | P2 | completed | 62 | SK Life Science, Inc. | Aug 2007 |
Carisbamate clinical trials: frequently asked questions
- How many Carisbamate clinical trials are there?
- 13 Carisbamate clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 11 are marked completed.
- Are Carisbamate clinical trials recruiting in 2026?
- Yes — 1 Carisbamate trial is actively recruiting in 2026, with 7 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Carisbamate being studied for?
- Carisbamate is being studied for Epilepsy, Complex Partial, Lennox Gastaut Syndrome, Epilepsy, Seizures, Focal Motor Epilepsy and 17 more. The trials are grouped by indication on this page.
- What phase is Carisbamate in?
- Carisbamate clinical trials span 5 Phase 3, 4 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Carisbamate clinical trials?
- The lead sponsor across the most Carisbamate trials is SK Life Science, Inc., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Carisbamateas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: